SNY 賽諾菲安萬特

添加自選

50.030
+0.800+1.63%

收盤價 05/01 16:00 (美東)

50.030
0.0000.00%

盤後 19:58 (美東)

1248.97億總市值25.87市盈率TTM

關於賽諾菲安萬特公司

賽諾菲開發和銷售專注於腫瘤學、免疫學、心血管疾病、糖尿病、非處方藥和疫苗的藥物。然而，該公司在2019年底決定退出心臟代謝領域，這可能會減少該公司在這個大型治療領域的足跡。該公司提供種類繁多的藥物，其最高收入來源Dupixent僅佔總銷售額的20%以上，但利潤與再生元分享。總收入的約40%來自美國，25%來自歐洲。新興市場佔其餘收入的大部分。

公司介紹

公司代碼SNY

公司名稱賽諾菲安萬特

成立日期1994

CEOMr. Paul Hudson

所屬市場納斯達克

員工數量87994

證券類型存託憑證（普通股）

ADS轉換比例2.0 : 1.0

年結日12-31

公司地址46, avenue de la Grande Armée

城市Paris

省份法蘭西島

國家法國

郵編75017

電話33-1-53-77-40-00

網址http://www.sanofi.com

董事高管

姓名
職務
年薪

Paul Hudson
Director and Chief Executive Officer
553.40萬

Jean-Baptiste Chasseloup De Chatillon
Executive Vice President and Chief Financial Officer
--

Natalie Bickford
Executive Vice President and Chief People Officer
--

Emmanuel Frenehard
Executive Vice President and Chief Digital Officer
--

Madeleine Roach
Executive Vice President, Business Operations
--

Brian Foard
Executive Vice President, Specialty Care
--

Julie Van Ongevalle
Executive Vice President, Consumer Healthcare
--

Olivier Charmeil
Executive Vice President, General Medicines
--

Roy Papatheodorou
Executive Vice President and General Counsel
--

Thomas Triomphe
Executive Vice President, Vaccines
--

Houman Ashrafian
Executive Vice President and Head of Research and Development
--

Brendan O'Callaghan
Executive Vice President, Global Manufacturing & Supply
--

Frederic Oudea
Chairman of the Board
--

Yann Tran
Director
4.20萬

Barbara Lavernos
Director
4.75萬

Wolfgang Laux
Director
4.20萬

Christophe Babule
Director
12.90萬

Dr. Antoine Yver, M.D.,M.Sc.
Independent Director
--

Carole Ferrand
Independent Director
--

Rachel Duan
Independent Director
11.80萬

Lise Kingo
Independent Director
9.88萬

Diane Souza
Independent Director
16.75萬

Thomas Sudhof
Independent Director
14.55萬

Fabienne Lecorvaisier
Independent Director
14.55萬

Patrick Kron
Independent Director
14.83萬

Gilles Schnepp
Independent Director
15.10萬

Emile Voest
Independent Director
--

分析

分析師評級

暫無數據

目標價預測

暫無數據

熱議

美股

綜合熱度